APC and breast carcinoma: This suggests that the expression of APC was not the only factor regulating the activity of MRP1, and it was not the main driver of APC-deficient DOX resistance, ultimately supporting the inhibition of MDR1 as a potential therapeutic target in APC-deficient breast cancer.